Alpeve

Alpeve is a brand of alpelisib, a selective inhibitor of phosphoinositide 3-kinase (PI3K) delta. It is primarily used in the treatment of advanced or metastatic breast cancer, specifically in patients whose tumors have a specific genetic alteration known as PIK3CA mutation. The drug works by inhibiting the PI3K delta enzyme, which is involved in the regulation of cell growth and survival. By blocking this enzyme, alpelisib can help slow the growth of cancer cells and potentially improve survival rates in patients with PIK3CA-mutated breast cancer.

Alpeve was approved by the U.S. Food and Drug Administration (FDA) in 2019 for the treatment of adult patients with PIK3CA-mutated, hormone receptor-positive, HER2-negative advanced or metastatic breast cancer who have received at least two prior systemic therapies. The approval was based on the results of the phase III ALTERED trial, which demonstrated that alpelisib, in combination with fulvestrant, provided a significant improvement in progression-free survival compared to fulvestrant alone.

The most common side effects of alpeve include fatigue, diarrhea, nausea, and constipation. Serious side effects may include an increased risk of infections, low blood cell counts, and liver problems. It is important for patients to discuss the potential benefits and risks of alpeve with their healthcare provider before starting treatment.

Alpeve is available in tablet form and is typically taken orally once daily. The dosage is determined by the patient's weight and should be adjusted as needed based on their response to treatment and any side effects experienced. Patients should follow their healthcare provider's instructions for taking alpeve and report any concerning symptoms or side effects promptly.